Rheumatology Strong — SLEDAI-2K 2002; international standard
SLEDAI-2K for SLE Disease Activity
Systemic Lupus Erythematosus Disease Activity Index 2000. 24-item weighted score measuring disease activity across 9 organ systems in the preceding 10 days.
References
- Gladman DD et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996.
- Gladman D, Ibañez D, Urowitz M. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Obinutuzumab (Anti-CD20 — Lupus Nephritis) · Glycoengineered Type II Anti-CD20 Monoclonal Antibody
- Hydroxychloroquine · Antimalarial — Lupus / Dermatoses
- Belimumab (Cutaneous Lupus) · BLyS/BAFF Inhibitor (Anti-B-Lymphocyte Stimulator)
- Natalizumab · Disease-Modifying Therapy — MS (Anti-VLA-4 Monoclonal Antibody)
- Cyclophosphamide (Nephrology) · ANCA Vasculitis / Lupus Nephritis
- Belimumab (Lupus Nephritis) · Lupus Nephritis
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.